AvKARE, Inc. (United States) has no DMF, CEP or site registration linked in our records. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “AvKARE, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/avkare-inc

Overview

AvKARE, Inc. is a leading provider in the pharmaceutical distribution sector, specializing in servicing the healthcare needs for hospitals, healthcare facilities, and the government. As a private company, AvKARE has established a reputation for quality and reliability in the distribution of pharmaceuticals.

Core services & business areas

Pharmaceutical DistributionSales and MarketingLogisticsRegulatory Affairs

Therapeutic areas

FDA compliance signals

50 FDA enforcement records linked to this company.

  • recall — Class II2026-03-04

    Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.

  • recall — Class II2026-01-14

    Out of specification for dissolution.

  • recall — Class II2025-10-15

    Failed Content Uniformity Specifications

  • recall — Class II2025-09-17

    Presence of a foreign substance.

  • recall — Class II2025-09-17

    Presence of a foreign substance.

  • recall — Class III2025-07-09

    Failed Impurity/Degradation Specifications

  • recall — Class III2025-07-09

    Failed Impurity/Degradation Specifications

  • recall — Class II2025-06-18

    Failed Dissolution Specifications

  • recall — Class II2025-06-18

    Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules

  • recall — Class II2025-02-26

    Subpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 105%)

  • recall — Class II2025-02-19

    Out of Specification for Dissolution

  • recall — Class II2025-01-08

    Failed Dissolution Specifications

  • recall — Class III2025-01-08

    LABELING: LABEL MIX-UP

  • recall — Class III2025-01-08

    LABELING: LABEL MIX-UP

  • recall — Class II2024-12-11

    CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

  • recall — Class II2024-12-11

    CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

  • recall — Class II2024-12-11

    CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

  • recall — Class II2024-12-11

    Labeling: Label Mix-Up

  • recall — Class II2024-12-11

    Labeling: Label Mix-Up

  • recall — Class I2024-04-24

    Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.

  • recall — Class II2023-09-13

    Cases of Sodium Fluoride 1.1% Prescription Dental Toothpaste may contain cartons labeled as Capsaicin Cream 0.025% but contain correctly labeled tubes of Sodium Fluoride 1.1% Prescription Dental Toothpaste

  • recall — Class II2023-09-13

    Product mix-up: Cartons labeled Capsaicin Cream 0.025% may contain tubes of Sodium Fluoride 1.1% Prescription Dental Toothpaste

  • recall — Class III2023-06-21

    Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

  • recall — Class II2023-01-04

    Failed impurities/degradation specifications: Out of specification for unknown impurities.

  • 4832022-11-02

    Procedures not in writing, fully followed

  • recall — Class III2022-08-17

    Labeling: Label Error on Declared Strength

  • recall — Class III2021-06-23

    Failed Impurities Specification: Out of specification when measuring the impurity degradant D level.

  • recall — Class I2020-12-23

    Product mix-up: Bottles of sildenafil and trazodone were inadvertently packaged together during bottling at a 3rd party facility.

  • recall — Class II2020-12-23

    Product mix-up: Bottles of sildenafil and trazodone were inadvertently packaged together during bottling at a 3rd party facility.

  • recall — Class II2020-11-18

    Failed Dissolution Specifications

  • recall — Class II2020-06-24

    CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

  • recall — Class II2020-06-24

    CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

  • recall — Class III2020-06-10

    Presence of Foreign Substance consistent with granules from desiccant packs used during storage

  • recall — Class II2020-01-22

    Failed Impurities/Degradation Specifications: High out of specification results for related compounds.

  • recall — Class II2019-12-04

    CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

  • recall — Class II2019-12-04

    CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

  • recall — Class II2019-11-06

    CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

  • recall — Class II2019-11-06

    CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

  • recall — Class II2019-09-18

    Failed Stability Specifications.

  • recall — Class II2019-05-08

    CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.

  • recall — Class II2019-05-08

    CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.

  • recall — Class III2019-04-17

    Failed Impurities/Degradation Specifications; 18 month long term stability study (manufacturer)

  • recall — Class II2019-03-27

    CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified

  • recall — Class II2019-03-27

    CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified

  • recall — Class II2019-03-27

    CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified

  • recall — Class III2019-03-20

    Failed Dissolution Specifications

  • recall — Class II2018-12-05

    Microbial Contamination of Non-Sterile Product: Presence of Pseudomonas aeruginosa in product

  • recall — Class II2018-09-12

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

  • recall — Class II2018-09-12

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

  • recall — Class II2018-09-12

    CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

For suppliers

Is this AvKARE, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.